Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford, OX3 9DU, UK.
Fertiaguerrevere Fertility Clinic, Caracas, 1012, Venezuela.
J Assist Reprod Genet. 2020 Apr;37(4):855-863. doi: 10.1007/s10815-020-01710-z. Epub 2020 Feb 7.
To investigate the impact of a 3-month course of intracortical injections of autologous platelet-rich plasma (PRP) upon ovarian reserve markers versus no intervention in women with low ovarian reserve prior to undergoing assisted reproductive technology (ART).
Prospective controlled, non-randomized comparative study conducted in a private fertility clinic, in Venezuela. Women with abnormal ovarian reserve markers (FSH, AMH and AFC) who declined oocyte donation were allocated to one of the following groups according to patient choice: monthly intracortical ovarian PRP injections for three cycles, or no intervention. Primary outcomes were the change in FSH, AMH and AFC pre- and post-treatment. Secondary outcomes included the number of oocytes collected and fertilized, biochemical/clinical pregnancy rates and miscarriage and live birth rates.
Eighty-three women were included, of which 46 received PRP treatment and 37 underwent no intervention. Overall median age was 41 years (IQR 39-44). There were no demographic differences between the study groups. At the 3-month follow-up, women treated with PRP experienced a significant improvement in FSH, AMH and AFC, whereas there was no change in the control group. Furthermore, overall rates of biochemical (26.1% versus 5.4%, P = 0.02) and clinical pregnancy (23.9% versus 5.4%, P = 0.03) were higher in the PRP group, while there was no difference in the rates of first trimester miscarriage and live birth between groups.
PRP injections are effective and safe to improve markers of low ovarian reserve prior to ART, although further evidence is required to evaluate the impact of PRP on pregnancy outcomes.
研究在接受辅助生殖技术 (ART) 之前,低卵巢储备的妇女接受 3 个月的自体富血小板血浆 (PRP) 皮质内注射对卵巢储备标志物的影响与不干预相比。
在委内瑞拉的一家私人生育诊所进行的前瞻性对照、非随机比较研究。根据患者选择,将卵巢储备标志物(FSH、AMH 和 AFC)异常且拒绝捐卵的妇女分配到以下组之一:每月皮质内卵巢 PRP 注射 3 个周期,或不干预。主要结局是治疗前后 FSH、AMH 和 AFC 的变化。次要结局包括采集和受精的卵母细胞数量、生化/临床妊娠率以及流产和活产率。
共纳入 83 例患者,其中 46 例接受 PRP 治疗,37 例未接受干预。总体中位年龄为 41 岁(IQR 39-44)。研究组之间无人口统计学差异。在 3 个月的随访中,接受 PRP 治疗的妇女的 FSH、AMH 和 AFC 显著改善,而对照组无变化。此外,PRP 组的生化妊娠率(26.1%比 5.4%,P=0.02)和临床妊娠率(23.9%比 5.4%,P=0.03)总体较高,而两组的早期流产和活产率无差异。
PRP 注射在 ART 之前改善低卵巢储备的标志物是有效且安全的,尽管需要更多证据来评估 PRP 对妊娠结局的影响。